Physical Review Letters, ISSN 0031-9007, 12/2014, Volume 113, Issue 23
The pT-differential production cross sections of the prompt charmed mesons D0, D+, D∗+, and Ds+ and their charge conjugate in the rapidity interval...
Physics and Astronomy(all)
Physics and Astronomy(all)
Journal Article
Physics Letters B, ISSN 0370-2693, 01/2014, Volume 728, pp. 616 - 621
A search for the bound state (the lightest kaonic nucleus) has been performed using the reaction at at LEPS/SPring-8. The differential cross section of the...
Photo-production | Antikaon–nucleon physics | Kaonic nuclei | Antikaon-nucleon physics | Nuclear Experiment | Nuclear and High Energy Physics
Photo-production | Antikaon–nucleon physics | Kaonic nuclei | Antikaon-nucleon physics | Nuclear Experiment | Nuclear and High Energy Physics
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9859, pp. 2095 - 2128
Summary Background Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health...
Internal Medicine | CHILD-MORTALITY | MEDICINE, GENERAL & INTERNAL | COMMUNITY-ACQUIRED PNEUMONIA | HOSPITALIZED-PATIENTS | PUBLIC-HEALTH UTILITY | MILLENNIUM DEVELOPMENT GOALS | NONCOMMUNICABLE DISEASE | MATERNAL MORTALITY | 187 COUNTRIES | NATIONAL CAUSES | RESPIRATORY SYNCYTIAL VIRUS | Age Factors | Humans | Middle Aged | Child, Preschool | Infant | Male | Mortality - trends | Young Adult | Adolescent | Global Health - statistics & numerical data | Sex Factors | Aged, 80 and over | Adult | Cause of Death - trends | Female | Aged | Child | Infant, Newborn | Causes of | Mortality | Research | Health care | Medical research | Disease | Acquired immune deficiency syndrome--AIDS | Fatalities | Product development | Cause of Death | Life Sciences | Human health and pathology | Infectious diseases | World Health
Internal Medicine | CHILD-MORTALITY | MEDICINE, GENERAL & INTERNAL | COMMUNITY-ACQUIRED PNEUMONIA | HOSPITALIZED-PATIENTS | PUBLIC-HEALTH UTILITY | MILLENNIUM DEVELOPMENT GOALS | NONCOMMUNICABLE DISEASE | MATERNAL MORTALITY | 187 COUNTRIES | NATIONAL CAUSES | RESPIRATORY SYNCYTIAL VIRUS | Age Factors | Humans | Middle Aged | Child, Preschool | Infant | Male | Mortality - trends | Young Adult | Adolescent | Global Health - statistics & numerical data | Sex Factors | Aged, 80 and over | Adult | Cause of Death - trends | Female | Aged | Child | Infant, Newborn | Causes of | Mortality | Research | Health care | Medical research | Disease | Acquired immune deficiency syndrome--AIDS | Fatalities | Product development | Cause of Death | Life Sciences | Human health and pathology | Infectious diseases | World Health
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The...
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article